Fuzheng Huayu Capsule Attenuates Hepatic Fibrosis by Inhibiting Activation of Hepatic Stellate Cells

Table 3

Changes in ALT, AST, Alb, and TBiL in both groups before and after treatment.

	NAs group				NAs + FZHY group
	n	Pre	Post	Post-Pre	n	Pre	Post	Post-Pre
ALT (IU/L)	50	54.04 ± 24.73	39.40 ± 19.02^▲	−11.14 ± 25.72	50	49.30 ± 25.29	28.50 ± 9.90^△	−21.89 ± 25.38
AST (IU/L)	50	59.79 ± 24.56	41.04 ± 29.93^▲	−15.05 ± 36.42	50	53.77 ± 24.52	29.71 ± 13.60^△	−23.55 ± 23.10
Alb (g/L)	50	35.38 ± 7.82	36.94 ± 8.09	2.92 ± 16.76	50	36.06 ± 7.96	35.91 ± 9.04	−1.66 ± 15.76
TBiL (mmol/L)	50	25.03 ± 12.85	26.20 ± 16.12	2.64 ± 16.18	50	25.97 ± 12.39	26.03 ± 14.89	−2.11 ± 12.83

, ^▲ versus the Pre of NAs group; versus the Pre of NAs + FZHY group. Alb, serum albumin; TBiL, serum total bilirubin; ALT, serum alanine aminotransferase; AST, serum aspartate aminotransferase.